Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

Antibe Therapeutics Inc(Pre-Merger) > Approved for Phase 111 in the US
View:
Post by nozzpack on Aug 13, 2021 2:23pm

Approved for Phase 111 in the US

 U.S. Food and Drug Administration (“FDA”) has already cleared the Company’s Investigational New Drug (“IND”) application for otenaproxesul, in development for the treatment of osteoarthritis pain.


This enables Antibe to undertake human clinical trials in the U.S.; as previously announced, Antibe anticipates initiating its Phase III program later this year.

They provided a ton of  a comprehensive package of preclinical and clinical data in a submission comprising more than 55,000 pages.

So, this minor issue does not prevent phase 111 clinical trials from proceeding in the US.

It is merely precautionary and may be nothing more than patient specific issue

Comment by MrMugsy on Aug 13, 2021 3:09pm
I don't think the company believes it's patient specific - way past that - but let's see what the September's update includes. If the drug is more potent than even they expected, they need to find the lowest effective dose. You wouldn't want to go to Phase 3 and run into an FDA stoppage.
Comment by nozzpack on Aug 13, 2021 4:02pm
U know nothing about what the company thinks. There are many issues related to anomalous and transient LFS from flawed patient selection to idiopathic presents. Surely FDA has never genuflected in the past..
Comment by MrMugsy on Aug 13, 2021 5:38pm
hahaha. that's pretty agressive NOZZ. you say that with such confidence Who's genuflecting?
Comment by muto412 on Aug 15, 2021 8:42pm
You're right they won't 'genuflect'. However, Dr. Stauffer has experience with the FDA...he has an understanding of the space and can provide solid guidance on FDA procedures.  "Dr. Stauffer practiced frontline medicine for a decade, including eight years as a US Navy general practice physician. He then joined the US Food and Drug Administration (“FDA”) as a Medical ...more  
Comment by 3burtc on Aug 13, 2021 8:41pm
Yes it does prevent phase3. You see friend if they don't figure out what went wrong. Phase 3 will fail and there goes 60 million. So many questions now about mgnt, especially Wallace. These guy's have lost the confidence of the investment community and it will be tough to regain that trust. I wonder what Nuance thinks? They put up 27 million cdn and now this?
Comment by Daydream2 on Aug 14, 2021 11:25am
Also what does Bloom & Burton Co. thinks of all this. A few of their tens of millions in investment have evaporated.
Comment by WalkOverTheStrt on Aug 14, 2021 5:56pm
It's a numbers game to the BPs and investment funds.. Do you really think they had everything at stake on antibe.... Claculated risk and with it many other plays that will pan out. Also Antobe's story is not over and far from it. Delayed yes but HS2 likely has a place in the medical world...
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities